DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Umbralisib
Umbralisib
Antineoplastic Agents
PI3K Inhibitors in Cancer: Clinical Implications and Adverse Effects
Optumrx Brand Pipeline Forecast
PRIOR AUTHORIZATION CRITERIA for APPROVAL Initial Evaluation Target Agent(S) Will Be Approved When ONE of the Following Is Met: 1
UKONIQ™ (Umbralisib) Tablets, for Oral Use • Severe Cutaneous Reactions: Withhold Treatment, Reduce Dose, Or Initial U.S
Antibodies to Watch in 2021 Hélène Kaplona and Janice M
How We Treat Mature B-Cell Neoplasms (Indolent B-Cell Lymphomas)
Standard Oncology Criteria C16154-A
American Society of Hematology (ASH) Annual Meeting December 5-8, 2020
Ukoniq (Umbralisib) Tablets
Master Trial List April 2021 ***New & Reopened Trials Highlighted in Green!***
Treating Non-Hodgkin Lymphoma If You’Ve Been Diagnosed with Non-Hodgkin Lymphoma, Your Treatment Team Will Discuss Your Options with You
UKONIQ Vermont Disclosure Long Form 3.22.21
ASCO 2021: Advances in Waldenström Macroglobulinemia
Stembook 2018.Pdf
Drug Coverage Guidelines
Current Treatment Options for WM
Oncology Drug Reference Guide
Top View
Chronic Lymphocytic Leukemia (CLL) for Patients and Their Families
Understanding Mantle Cell Lymphoma: Relapsed/Refractory
Partnerre Trigger Pharmaceuticals (At 2.16.21) Code Brand Name Trade Name Code Brand Name Trade Name J0800 Acthar®
Towards Personalized Treatment in Waldenström Macroglobulinemia
Tenncare Autoexempt List September 1, 2021 This Is a Current List of the Drugs and Supplies That Do Not Count Toward an Enrollee’S Monthly Drug Limit
Targeting PI3K in Cancer: Mechanisms and Advances in Clinical Trials Jing Yang, Ji Nie, Xuelei Ma, Yuquan Wei, Yong Peng and Xiawei Wei*
Cellular Cytotoxicity of Next-Generation CD20 Monoclonal Antibodies Karl R
A Phase 1/2 Study of Umbralisib Ublituximab and Venetoclax in Patients with Relapsed Or Refractory Chronic Lymphocytic Leukemia (CLL)
Oral Oncology (O-Z)
Partnerre Trigger Pharmaceuticals (At 5.21.21) Code Brand Name Generic Name Code Brand Name Generic Name J3590 Abecma®
University of Nebraska Medical Center (UNMC), Bellevue Medical Center (BMC), and Village Point Cancer Center May Be Eligible for This Trial
Umbralisib (TGR-1202) in Patients with Relapsed/Refractory Lymphoid Malignancies
2020 Medicines in Development ꟷ Cancer
TAG Mail – 25 June 2020
Orange Book February 2021 Changes List
Drug Benefit Guide
State and Specialty Pharmacy Drug Reimbursement Rates
Oncology Medications Policy (1403)